{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:05:45Z","timestamp":1778216745719,"version":"3.51.4"},"reference-count":38,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Royal Marsden NHS Foundation Trust"},{"name":"Elekta"},{"name":"JP Moulton Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>HERMES is a phase II trial of MRI-guided daily-adaptive radiotherapy (MRIgART) randomising men with localised prostate cancer to either 2-fractions of SBRT with a boost to the tumour or 5-fraction SBRT. In the context of this highly innovative regime the dose delivered must be carefully considered. The first ten patients recruited to HERMES were analysed in order to establish the dose received by the targets and organs at risk (OARS) in the context of intrafraction motion. A regression analysis was performed to measure how the volume of air within the rectum might further impact rectal dose secondary to the electron return effect (ERE). One hundred percent of CTV target objectives were achieved on the MRI taken prior to beam-on-time. The post-delivery MRI showed that high-dose CTV coverage was achieved in 90% of sub-fractions (each fraction is delivered in two sub-fractions) in the 2-fraction cohort and in 88% of fractions the 5-fraction cohort. Rectal D1 cm3 was the most exceeded constraint; three patients exceeded the D1 cm3 &lt; 20.8 Gy in the 2-fraction cohort and one patient exceeded the D1 cm3 &lt; 36 Gy in the 5-fraction cohort. The volume of rectal gas within 1 cm of the prostate was directly proportional to the increase in rectal D1 cm3, with a strong (R = 0.69) and very strong (R = 0.90) correlation in the 2-fraction and 5-fraction cohort respectively. Dose delivery specified in HERMES is feasible, although for some patients delivered doses to both target and OARs may vary from those planned.<\/jats:p>","DOI":"10.3390\/cancers16112073","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T06:08:14Z","timestamp":1717049294000},"page":"2073","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Stereotactic Body Radiotherapy (SBRT) to Localised Prostate Cancer in the Era of MRI-Guided Adaptive Radiotherapy: Doses Delivered in the HERMES Trial Comparing Two- and Five-Fraction Treatments"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-8736","authenticated-orcid":false,"given":"Rosalyne","family":"Westley","sequence":"first","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK"},{"name":"Radiotherapy and Imaging Division, Institute of Cancer Research, London SM2 5NG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Casey","sequence":"additional","affiliation":[{"name":"Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6736-3349","authenticated-orcid":false,"given":"Adam","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-5174","authenticated-orcid":false,"given":"Sophie","family":"Alexander","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK"},{"name":"Radiotherapy and Imaging Division, Institute of Cancer Research, London SM2 5NG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4351-8136","authenticated-orcid":false,"given":"Simeon","family":"Nill","sequence":"additional","affiliation":[{"name":"Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Murray","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK"},{"name":"Radiotherapy and Imaging Division, Institute of Cancer Research, London SM2 5NG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ragu","family":"Ratnakumaran","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK"},{"name":"Radiotherapy and Imaging Division, Institute of Cancer Research, London SM2 5NG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Pathmanathan","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK"},{"name":"Radiotherapy and Imaging Division, Institute of Cancer Research, London SM2 5NG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Oelfke","sequence":"additional","affiliation":[{"name":"Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Dunlop","sequence":"additional","affiliation":[{"name":"Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison C.","family":"Tree","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK"},{"name":"Radiotherapy and Imaging Division, Institute of Cancer Research, London SM2 5NG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2005.06.009","article-title":"The \u03b1\/\u03b2 ratio for prostate cancer: What is it, really?","volume":"76","author":"Bentzen","year":"2005","journal-title":"Radiother. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2017.12.011","article-title":"Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials","volume":"100","author":"Vogelius","year":"2018","journal-title":"Radiat. Oncol. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/cncr.30093","article-title":"PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer","volume":"122","author":"McPartlin","year":"2016","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijrobp.2019.05.014","article-title":"Testosterone Levels and Sexual Quality of Life after Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials","volume":"105","author":"Yuan","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"109503","DOI":"10.1016\/j.radonc.2023.109503","article-title":"Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion\u2014Results from the 2SMART phase 2 trial","volume":"181","author":"Ong","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"109441","DOI":"10.1016\/j.radonc.2022.109441","article-title":"SBRT focal dose intensification using an MR-Linac adaptive planning for intermediate-risk prostate cancer: An analysis of the dosimetric impact of intra-fractional organ changes","volume":"179","author":"Brennan","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"N229-37","DOI":"10.1088\/0031-9155\/54\/12\/N01","article-title":"Integrating a 1.5 T MRI scanner with a 6 MV accelerator: Proof of concept","volume":"54","author":"Raaymakers","year":"2009","journal-title":"Phys. Med. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"616291","DOI":"10.3389\/fonc.2020.616291","article-title":"MR-Guided Radiotherapy for Prostate Cancer","volume":"10","author":"Tocco","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijrobp.2023.09.032","article-title":"Interim toxicity analysis from the randomised HERMES trial of 2- and 5-fraction MRI-guided adaptive prostate radiation therapy","volume":"118","author":"Westley","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_18","first-page":"100604","article-title":"GI factors, potential to predict prostate motion during radiotherapy; a scoping review","volume":"40","author":"Alexander","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1088\/0031-9155\/50\/7\/002","article-title":"Integrating a MRI scanner with a 6 MV radiotherapy accelerator: Dose increase at tissue-air interfaces in a lateral magnetic field due to returning electrons","volume":"50","author":"Raaijmakers","year":"2005","journal-title":"Phys. Med. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/acm2.12903","article-title":"Impact of varying air cavity on planning dosimetry for rectum patients treated on a 1.5 T hybrid MR-linac system","volume":"21","author":"Subashi","year":"2020","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3389\/fonc.2020.01328","article-title":"The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy","volume":"10","author":"Christodouleas","year":"2020","journal-title":"Front Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_23","first-page":"35","article-title":"Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: Initial clinical experiences and assessment of delivered doses compared to a C-arm linac","volume":"23","author":"Dunlop","year":"2020","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.radonc.2022.09.004","article-title":"Clinical application of a sub-fractionation workflow for intrafraction re-planning during prostate radiotherapy treatment on a 1.5 Tesla MR-Linac: A practical method to mitigate intrafraction motion","volume":"176","author":"Willigenburg","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jmir.2023.05.016","article-title":"Advantages of MR-guided radiotherapy with comprehensive motion management using Elekta Unity","volume":"54","author":"Soh","year":"2023","journal-title":"J. Med. Imaging Radiat. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.radonc.2013.09.025","article-title":"High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: Acute toxicity","volume":"110","author":"Hoskin","year":"2014","journal-title":"Radiother. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ijrobp.2015.10.011","article-title":"Outcomes Associated with 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer","volume":"94","author":"Jawad","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.radonc.2016.10.019","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy","volume":"122","author":"Morton","year":"2017","journal-title":"Radiother. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.21873\/anticanres.16597","article-title":"Towards Personalization of Planning Target Volume Margins Fitted to the Abdominal Adiposity in Localized Prostate Cancer Patients Receiving Definitive or Adjuvant\/Salvage Radiotherapy: Suggestive Data from an ExacTrac vs. CBCT Comparison","volume":"43","author":"Ferini","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_30","first-page":"1379","article-title":"A ten-year-long update on radiation proctitis among prostate cancer patients treated with curative external beam radiotherapy","volume":"35","author":"Ferini","year":"2021","journal-title":"In Vivo Int. Inst. Anticancer. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.21873\/anticanres.14981","article-title":"How much daily image-guided volumetric modulated arc therapy is useful for proctitis prevention with respect to static intensity modulated radiotherapy supported by topical medications among localized prostate cancer patients?","volume":"41","author":"Ferini","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_33","first-page":"33","article-title":"Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT","volume":"10","author":"Parikh","year":"2021","journal-title":"Appl. Radiat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2200215","DOI":"10.1200\/GO.22.00215","article-title":"Benefits of Adopting Hypofractionated Radiotherapy as a Standard of Care in Low-and Middle-Income Countries","volume":"8","author":"Kraus","year":"2022","journal-title":"JCO Glob. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.14338\/IJPT-16-00007.1","article-title":"Bacterial Urinary Tract Infection after Transrectal Placement of Fiducial Markers prior to Proton Radiotherapy for Prostate Cancer","volume":"3","author":"Mendenhall","year":"2016","journal-title":"Int. J. Part. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.adro.2017.03.005","article-title":"Simulating intrafraction prostate motion with a random walk model","volume":"2","author":"Pommer","year":"2017","journal-title":"Adv. Radiat Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Fredman, E., Icht, O., Moore, A., Bragilovski, D., Kindler, J., Golan, S., and Limon, D. (2024). SABR-Dual: A phase II\/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12165-1"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wolfe, S., Diven, M.A., Marciscano, A.E., Zhou, X.K., Kishan, A.U., Steinberg, M.L., Miccio, J.A., Camilleri, P., and Nagar, H. (2023). A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT). BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11430-z"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/11\/2073\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:50:59Z","timestamp":1760107859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/11\/2073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["cancers16112073"],"URL":"https:\/\/doi.org\/10.3390\/cancers16112073","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}